![The breaking news round-up: Decagear launches today, Pimax announces new headsets, and more! [APRIL FOOL’S]](https://i0.wp.com/skarredghost.com/wp-content/uploads/2025/03/lawk_glasses_handson.jpg?fit=1366%2C1025&ssl=1)
Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs appeared first on MedCity News.
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission.
The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs appeared first on MedCity News.
